drugset / Trial / NCT03093701
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.
Timeline
- Start
- 2017-04-01
- Primary completion
- 2019-02-04
- Completion
- 2019-02-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 0.36 mg | — |
| Subject | Dexamethasone | Small molecule | 0.6 mg | — |
| Subject | Dexamethasone | Small molecule | 0.84 mg | — |